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Abstract
Background: Long-term survivors of childhood malignancies are at 
increased risk of experiencing treatment-related morbidities. Survival into 
late adulthood in these children provides ample time for the acquisition of 
long-term sequelae. This study aimed to determine the late adverse effects 
among long-term survivors of childhood cancer from a low-income country 
perspective. Materials and Methods: Data were retrospectively collected 
from review of charts of patients aged under 18 years at the time of their 
primary diagnosis between 1 January, 1995, and 31 December, 2008, and 
who survived for at least 5 years after completion of their treatment. Analysed 
data included demographics, cancer type, treatment modality, types of 
chemotherapy agents administered and specific late morbidities including 
frequency of azoospermia, oligospermia, endocrine abnormalities, hearing 
and pulmonary function impairment and cardiac dysfunction among the 
long-term survivors of cancer. Results: The total number of patients was 
300 with a mean age of 18 ± 2 years. The male to female ratio was 2.7:1. 
Median follow-up duration was 18 years (range: 5–25 years). Seventy-seven 
percent of patients were from Punjab, 20% were from Khyber Pakhtunkhwa 
and 3% were from other provinces. Fifty percent had a diagnosis of Hodgkin 
lymphoma, 17% had acute lymphoblastic leukaemia, 13% had non-Hodgkin 
lymphoma, 10% had germ cell tumours and 10% had other tumours. Fifty-
seven percent received chemotherapy, 23% had chemotherapy and 
radiotherapy, 15% had chemotherapy and surgery, 3% had chemotherapy, 
surgery and radiotherapy and 2% had only surgery. Notable long-term 
documented sequelae were; azoospermia/oligospermia in 64%, endocrine 
abnormalities in 25% with hypothyroidism in 13.5% and follicle-stimulating 
hormone and luteinizing hormone abnormalities in 11.5%, ototoxicity in 6.5%, 
impaired pulmonary function tests in 4.6%, cardiotoxicity in 2.4% and second 
malignancies (acute myeloid leukaemia and myelodysplastic syndrome) in 
1%. Conclusion: Childhood cancer survivors are at increased risk of adverse 
treatment-related sequelae and a long-term follow-up plan should be in place 
in centres where they receive treatment for their primary disease.
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Introduction
The combined 5-years overall survival of childhood 
cancer is around 80%.[1] Further improvement 
in survival is anticipated due to the continuing 
refinement of treatment modalities and improved 
supportive care. Children have an increased 
number of days to live after the successful 
treatment of their primary cancer. As a result, they 
have an increased chance of manifesting long-term 
complications of primary cancer and its treatment-
related sequelae.[2]
The primary treatment depends on the diagnosis 
and generally includes a combination of 
chemotherapy drugs with or without radiotherapy 
and surgery.[3] The type of long-term sequelae to 
which these survivors are prone partly depends 
on the combination of chemotherapeutic agents 
and adjuvant therapy including surgery and 
radiotherapy.[2,3] Adverse effects of cancer and its 
treatment in long-term survivors are a well-known 
phenomenon based on studies from the high-
income countries.[4] However, there has been 
limited research from low-income countries and the 
estimation of late adverse effects among survivors 
of cancer in low-income countries is usually an 
extrapolation from the results based on studies 
from the high-income countries. Disease nature, 
patient characteristics and socio-economic factors 
are different in low-income countries than those 
in high-income countries and, therefore, local 
studies are needed to truly estimate the burden 
of late complications in survivors of cancer in our 
population.[5]
This study aimed to determine the late adverse 
sequelae among long-term survivors of childhood 
cancer from a low-income country perspective.
Materials and Methods
This was a retrospective chart review of data from 
the electronic record of patients under 18 years of 
age who got treatment for their cancer at Shaukat 
Khanum Memorial Cancer Hospital and Research 
Centre from 1 January, 1995, to 31 December, 
2008. After approval from the institutional review 
board, patients who fulfilled the following criteria 






Data were analysed to determine each candidate’s 
cl inical and demographic characteristics, 
diagnosis, sex, age at the time of diagnosis, 
current age and survival duration since diagnosis 
and the type of therapy they received. Hodgkin 
lymphoma was treated with cyclophosphamide, 
vincristine, prednisone, dacarbazine/adriamycin, 
bleomycin, vinblastine and dacarbazine (ABVD) 
(cyclophosphamide, vincristine, prednisolone, 
adriamycin, bleomycin and vinblastine), OEPA/
ABVD (vincristine, etoposide, prednisone and 
ABVD) or chlorambucil, vinblastine, procarbazine 
and prednisolone (CHLVPP)/ABVD (chlorambucil, 
v inblas t ine ,  procarbaz ine,  doxorubic in , 
bleomycin, vincristine and etoposide). Burkitt 
lymphoma was treated as per UKCCSG NHL 
2003 guidel ines. [6,7] Acute lymphoblastic 
leukaemia patients received chemotherapy 
as per MRC UKALL XI/MRC ALL97 and UKALL 
2003 guidelines.[8,9] Retinoblastoma was treated 
with JOE chemotherapy (vincristine, etoposide 
and carboplatin).[10] Germ cell tumours were 
treated with JEB (carboplatin, etoposide and 
bleomycin) or BEP chemotherapy (cisplatin, 
etoposide and bleomycin).[11] Wilms tumour 
cases received chemotherapy as per children’s 
cancer and leukaemia group and COG’s Wilms 
tumour guideline (including nephrectomy, 
chemotherapy with  or  without  radiation 
depending on risk group).[12,13] Radiotherapy was 
given as per EuroNet radiotherapy guidelines in 
Hodgkin lymphoma, MRC UKALL XI/MRC ALL97 
in acute lymphoblastic leukaemia and UKCCSG 
in retinoblastoma and Wilms tumour.[14-16]
The modalities used for detecting late adverse 
sequelae were; echocardiography for cardiac 
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dysfunction, serum thyroid-stimulating hormone 
(TSH), free T4, testosterone, follicle-stimulating 
(FSH) and luteinizing hormone (LH) levels for 
endocrine abnormalities, seminal microscopy for 
sperm count, pure tone audiometry for hearing 
assessment and diffusing lung capacity for 
carbon monoxide (DLCO) for pulmonary function 
abnormalities.
Azoospermia was defined as the total absence 
of sperms from the ejaculate under the light 
microscope. Oligospermia was defined as sperm 
count <20 × 106/mL in the ejaculate under the light 
microscope. Ototoxicity was defined as an abnormal 
audiometric assessment of any degree according to 
the World Health Organization (WHO) classification 
of hearing impairment.[17] Cardiomyopathy was 
defined as a fractional shortening of < 28% or 
ejection fraction <55% or a decline of more than 
10% over any interval of time with or without 
associated symptoms. Abnormal pulmonary 
function tests were defined as the DLCO <80% 
from the predicted normal values for age and 
sex according to the American Thoracic Society 
guidelines.[18] Hypothyroidism was defined as lower 
than the normal age-adjusted values of Free T4 
with or without elevated TSH for age and gender.[19]
Toxicity evaluations were tailored according to 
the specific therapeutic exposures. Microscopic 
semen analysis was performed to determine 
azoospermia or oligospermia in children >13 
years of age who received procarbazine. Serum 
FSH, LH and testosterone levels were measured 
in those with azoospermia or oligospermia. 
Ejection fraction and fraction shortening as 
determined by echocardiography were used 
to evaluate cardiac dysfunction in children who 
received anthracyclines. Thyroid profile with T4, 
free T4 and TSH was used to determine thyroid 
status in children who received radiation to the 
neck. The audiometric examination was used 
to determine hearing dysfunction and DLCO 
to evaluate pulmonary dysfunction in survivors 
who received platinum-based chemotherapy or 
bleomycin. Hepatitis serology with HBsAg/Anti-
HBs/Anti-HCV was used to screen for hepatitis B and 
C in all patients and if positive, polymerase chain 
reaction was done to confirm the diagnosis. The 
frequency of toxicities attributed to radiation and 
chemotherapy agents was separately calculated. 
All patients were followed in late effects clinic 
according to institutional guidelines.
Statistical analysis was performed using SPSS 
software (Version 20.0; SPSS, Chicago, IL). 
Descriptive statistics were reported as frequencies 
and percentages for quantitative data. The Chi-
square test was used to calculate P-value for the 
determination of association between demography 
of the participants and the risk of acquisition of late 
adverse sequelae.
Results
The total number of patients included in the present 
investigation was 300. Among these, there were 
73% males. The mean age of study population was 
18 ± 2 years. The median follow-up duration was 18 
years (range: 5–25 years). Summary of these results, 
along with details of demographics of the cohort 
are given in Table 1.
Fifty percent of the survivors had the diagnosis 
of Hodgkin lymphoma at the time of their initial 
presentation [Table 2]. The most common treatment 
modality was chemotherapy alone (57%), followed 
by chemotherapy and radiotherapy (23%) and 
chemotherapy and surgery (15%) [Table  3]. The 
most commonly used chemotherapeutic agents 
were anthracycline (81%; 100–400 mg/m2), 
bleomycin (52%; 61–118 mg/m2), procarbazine 
(48%) and etoposide (17%; 500–2000 mg/m2). 
Depending on the protocol, radiotherapy dose 
was between 14 and 36 grey units.
The most common abnormalities were azoospermia/
oligospermia in 64% and endocrine abnormalities 
in 25% [Table 4]. Furthermore, 1% of the participants 
developed secondary malignancy (acute myeloid 
leukaemia and myelodysplastic). Thirty-three 
percent of the participants were studying in college 
or university, 7% of the participants were working, 
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4.6% of the participants were married and 2.9% of 
the participants had children.
Hypothyroidism was seen only in patients who 
received radiotherapy to the neck region. 
Ototoxicity was seen only in patients who received 
platinum-based chemotherapy as part of their 
treatment protocol. Pulmonary toxicity was seen 
only in patients who received bleomycin containing 
chemotherapy. Azoospermia/oligospermia was 
reported in patients who received procarbazine 
containing chemotherapy like CHLVPP/ABVD. 
Thirteen percent of the patients experienced single 
organ loss secondary to surgery in curative intent. 
In our cohort, unilateral enucleation was reported 
in 3.2%, nephrectomy in 1.9%, orchidectomy in 
1.9% and oophorectomy in 4.2%. We did not find 
any association between the rate of adverse effects 










Gender Males: Female ratio 2.7
Demographics Punjab 77% (231)
Khyber Pakhtunkhwa 20% (60)
Other (baluchistan, Gilgit-Baltistan 
and sindh)
3% (9)











Chemotherapy and surgery 15 (46)
Chemotherapy, surgery and 
radiotherapy
3 (10)















Audiometry 46 Ototoxicity (6.5)
Pulmonary 
function tests
181 Impaired diffusing lung 








Hodgkin lymphoma 50 (150)
Acute lymphoblastic leukaemia 17 (51)
Non-Hodgkin lymphoma 13 (39)
Germ cells tumour 10 (30)
Retinoblastoma 5 (15)
Others 5 (15)
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Discussion
It is estimated that one out of every 750 adults living 
today in the United States is a survivor of childhood 
cancer and that around 2/3rd of all patients still living 
30 years after their cancer treatment in childhood 
suffer from late complications.[20] A study regarding 
multiple system abnormalities in long-term survivors 
by Livinalli et al. from Brazil found that 27.4% of the 
patients had abnormal test results observed in any 
one system, including 47% in the endocrine and 
metabolic, 41.2% in the cardiovascular (including 
but not limited to cardiomyopathy), 29.4% in the 
musculoskeletal and 5.9% in auditory and renal 
systems.[21] Radiotherapy and alkylating agents have 
long been recognized as risk factors for second 
malignancies with a frequency of 3–7%.[22-27] In our 
cohort, 3% of the patients experienced a relapse of 
primary disease and 1% of the patients developed 
another malignancy (acute myeloid leukaemia/
myelodysplastic syndrome). All of these patients 
had received alkylating agents and radiotherapy as 
part of their treatment. Azoospermia/oligospermia 
was noted in 64% in our review which corresponds 
to reports by Wasilewski-Masker et al. who 
found infertility in 46% of patients of long-term 
survivors of childhood cancer and Niels et al. who 
found subnormal levels of inhibin B in 67%.[28,29] 
Inhibin B level was used as a surrogate marker 
for spermatogenesis in their study. We could not 
determine infertility in our patients because the 
majority of our patients were unmarried, and it is 
considered inappropriate in the local culture to 
ask patients to undergo fertility testing. We used 
azoospermia/oligospermia coupled with FSH as an 
indicator of deficient spermatogenesis instead of 
inhibin B. Alkylating agents, especially procarbazine 
and cyclophosphamide, are implicated in the 
causation of abnormalities in sperm count or 
morphology in published literature.[30,31] In our 
review, out of the 64% having azoospermia and 
oligospermia, 72% received procarbazine and/
or cyclophosphamide in their primary treatment, 
confirming the gonadal damage caused by these 
two agents. A study by Ramjaun et al. found 
that 14.7% long-term survivors of childhood 
cancer had echocardiographic evidence of 
myocardial dysfunction.[32] Mulrooney et al. 
reported cardiomyopathy in 7.4% cases of long-
term survivors.[33] An ongoing continual increase 
in the incidence of sustained echocardiographic 
abnormality was seen among patients treated 
with >250 mg/m2 doxorubicin at age <5 years, 
reaching 43% by 20 years of therapy. Hu et al. found 
cardiotoxicity in 1.5% recipients of anthracycline and 
reported that cumulative doses above 200 mg/m2 
correlated with the emergence of cardiotoxicity in 
these patients.[34] All of our patients who developed 
cardiomyopathy had received anthracyclines, but 
only 2.4% of the total percentage of these patients 
had echocardiographic abnormalities. Most of the 
patients were symptomatic with echocardiographic 
abnormalities and they were referred to cardiologist. 
This is lower than what is reported in the published 
literature probably due to the lesser cumulative 
doses of anthracyclines in our cohort as it was 
<100 mg/m2 in 150 patients and only five patients 
received doses over 400 mg/m2. Furthermore, 
another reason for lesser cardiac toxicity in our 
report may be shorter duration of follow-up as 
compared to studies mentioning greater cardiac 
toxicity with 20 years or more follow-up.
Kasteler et al. reported an increased incidence of 
pulmonary complications in survivors of childhood 
cancers.[35] Bleomycin and radiotherapy to chest 
region are well-known risk factors implicated in 
lung damage or abnormal pulmonary function 
tests in long-term survivors.[36] The majority of 
our patients (90%) with impaired DLCO had 
received bleomycin and radiotherapy for Hodgkin 
lymphoma. In our report, the lung toxicity was 
comparable to other studies.[36]
Endocrine abnormalities are more common in 
long-term survivors of cancers than the general 
population, especially among those who received 
radiotherapy to anatomic regions in close proximity 
to endocrine glands.[6,37] Endocrine hormone 
abnormalities reported in our report (25%) are in 
agreement with other international studies. Sklar 
et al. reported thyroid abnormalities in 34% of the 
patients with Hodgkin lymphoma, 79% of whom 
received radiotherapy as part of multimodality 
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treatment.[37] Radiotherapy to the neck region 
causes direct damage to the thyroid gland.[38] 
We agree with this finding as 30% of cases with 
hypothyroidism in our cohort occurred in Hodgkin 
lymphoma survivors who were given radiotherapy 
to the neck region. LH and FSH are affected in those 
who either receive cranial or testicular irradiation or 
orchidectomy as part of their treatment.[6]
Cisplatin is a commonly prescribed component of 
chemotherapy for germ cell tumours. It has been 
associated with permanent bilateral hearing loss 
in 10–75% of cases depending on the cumulative 
dose.[39] In our tested cohort, 6.5% had hearing 
impairment and among them 50% received cisplatin.
Organ loss in the form of amputative limb surgery, 
orchidectomy, nephrectomy and enucleation has 
three-fold morbidity. It has physiological, physical 
and psychological implications for the long-term 
survivors.[40] A study of 62 survivors of childhood 
acute lymphoblastic leukaemia and lymphoma 
reported selective neurocognition deficits rather 
than generalized cognitive dysfunction in these 
patients.[41] The occurrence of 1.3% of hepatitis B 
and/or C in our patients appears to be multifactorial. 
It can be partly explained by frequent blood 
transfusion needs and the immunocompromised 
status of this subset of patients.
To date, no scientific evidence exists that genetic 
and ethnic background correlates with outcomes 
in long-term cancer survivors.[42] However, a 
genetic component is postulated to play a role 
in the appearance of long-term adverse effects 
as the toxicity anchored by chemotherapeutic 
agents and radiotherapy is heterogeneous and 
non-linear. A study by Clemens et al. is assessing 
genetic determinants of ototoxicity during and 
after childhood cancer treatment, the results 
of their study are not yet available.[43] Results of 
another analysis by Van der Kooi et al. regarding 
the genetic variation in gonadal impairment in 
female survivors of childhood cancer are awaited.[44] 
Health insurance plays a pivotal role in ensuring the 
attendance of LTF clinics in cancer survivors. We did 
not perform genetic analysis of our patients who 
experienced toxicities due to the cost as testing 
were not available at our centre during the study 
period. Unfortunately, in low-income countries, the 
health insurance system is not well established. 
A study from the United States found a positive 
correlation between attendance in LTF clinics, and 
therefore early detection of adverse sequelae and 
insurance status of the patients.[45] In a multivariate 
analysis, Klosky et al. concluded that the absence of 
insurance correlated with an increased loss to LTF 
in cancer survivors.[46] Patients who experienced 
long-term complications in our cohort were 
referred to respective subspecialties for treatment. 
Patients who had amputation limb surgery were 
rehabilitated with prosthetic limbs and patients 
who had enucleation were offered prosthetic eye.
Our study had inherited limitations of a retrospective 
study design. We analysed limited parameters (due 
to cost) in long-term survivors in selected types 
of cancers (data were available only for the types 
of cancers treated at our centre). Psychological 
assessment and intelligence quotient were not 
calculated. In addition, the number of patients from 
Khyber Pakhtunkhwa was small and therefore the 
positive or negative impact of demography on 
adverse late effects among long-term survivors had 
limited significance in our review.
We conclude that a significant proportion of long-
term survivors of childhood cancer experience 
health-related issues due to primary cancer and 
its treatment. The association of ethnic and genetic 
factors with the appearance of complications in 
these patients requires further studies. Regular 
follow-up is suggested in cancer centres to screen 
patients for the expected complications which are 
partly explained by the type and agents used as 
treatment modality. Mobilization of social services 
may help improve the attendance of cancer 
survivors in long-term follow-up.
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